Amgen announces positive results from two Phase 3 BLINCYTO ® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared to conventional consolidation chemotherapy in pediatric patients with
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news